Wingo P A, Layde P M, Lee N C, Rubin G, Ory H W
JAMA. 1987 Jan 9;257(2):209-15.
We studied the association between estrogen replacement therapy (ERT) and the risk of breast cancer as part of the Cancer and Steroid Hormone Study. All subjects in the analysis were postmenopausal women enrolled from eight geographic areas. Women 25 to 54 years old with newly diagnosed breast cancer were identified through population-based tumor registries and diagnosed between Dec 1, 1980, and Dec 31, 1982. Controls were selected from the same eight geographic areas by the random digit dialing of residential telephone numbers. Analyses included 1369 cases and 1645 controls. Among women with bilateral oophorectomy, the relative risk of breast cancer for women who had ever used ERT was 1.3, compared with women who had never used ERT. Among women who had undergone hysterectomy but who still had at least one ovary, the relative risk was 1.1; among women who reported a natural menopause, the relative risk was 0.8. Overall, the risk of breast cancer did not appear to increase appreciably with increasing ERT duration or latency, even for durations and latencies of 20 years or longer.
作为癌症与类固醇激素研究的一部分，我们研究了雌激素替代疗法（ERT）与乳腺癌风险之间的关联。分析中的所有受试者均为来自八个地理区域的绝经后女性。通过基于人群的肿瘤登记处识别出年龄在25至54岁之间、新诊断为乳腺癌的女性，她们在1980年12月1日至1982年12月31日期间被确诊。通过随机拨打住宅电话号码从相同的八个地理区域中选取对照。分析包括1369例病例和1645名对照。在双侧卵巢切除术的女性中，曾经使用ERT的女性患乳腺癌的相对风险为1.3，而从未使用ERT的女性为参照。在接受子宫切除术但仍至少保留一个卵巢的女性中，相对风险为1.1；在自然绝经的女性中，相对风险为0.8。总体而言，即使ERT持续时间或潜伏期长达20年或更长时间，乳腺癌风险似乎也没有随着ERT持续时间或潜伏期的增加而明显增加。
